Kanada - Ingliż - Health Canada

pfizer canada ulc - filgrastim - solution - 300mcg - filgrastim 300mcg - hematopoietic agents

Kanada - Ingliż - Health Canada

pfizer canada ulc - filgrastim - solution - 480mcg - filgrastim 480mcg - hematopoietic agents

Kanada - Ingliż - Health Canada

pfizer canada ulc - filgrastim - solution - 300mcg - filgrastim 300mcg - hematopoietic agents

Kanada - Ingliż - Health Canada

pfizer canada ulc - filgrastim - solution - 480mcg - filgrastim 480mcg - hematopoietic agents

Iżrael - Ingliż - Ministry of Health

amgen europe b.v. - filgrastim - solution for injection - filgrastim 30 mu/ml - filgrastim - filgrastim - neupogen is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia.the safety and efficacy of neupogen are similar in adults and children receiving cytotoxic chemotherapy.neupogen is indicated for the mobilisation of peripheral blood progenitor cells (pbpcs).in patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (anc) of ≤ 0.5 × 109/l, and a history of severe or recurrent infections, long term administration of neupogen is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.neupogen is indicated for the treatment of persistent neutropenia (anc less than or equal to 1.0 × 109/l) in patients with advanced hiv infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.

Iżrael - Ingliż - Ministry of Health

amgen europe b.v. - filgrastim - solution for injection - filgrastim 48 mu / 0.5 ml - filgrastim - filgrastim - neupogen is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia.the safety and efficacy of neupogen are similar in adults and children receiving cytotoxic chemotherapy.neupogen is indicated for the mobilisation of peripheral blood progenitor cells (pbpcs).in patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (anc) of ≤ 0.5 × 109/l, and a history of severe or recurrent infections, long term administration of neupogen is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.neupogen is indicated for the treatment of persistent neutropenia (anc less than or equal to 1.0 × 109/l) in patients with advanced hiv infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.

Iżrael - Ingliż - Ministry of Health

amgen europe b.v. - filgrastim - solution for injection - filgrastim 30 mu / 0.5 ml - filgrastim - filgrastim - neupogen is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia.the safety and efficacy of neupogen are similar in adults and children receiving cytotoxic chemotherapy.neupogen is indicated for the mobilisation of peripheral blood progenitor cells (pbpcs).in patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (anc) of ≤ 0.5 × 109/l, and a history of severe or recurrent infections, long term administration of neupogen is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.neupogen is indicated for the treatment of persistent neutropenia (anc less than or equal to 1.0 × 109/l) in patients with advanced hiv infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.

Iżrael - Ingliż - Ministry of Health

teva israel ltd - filgrastim - solution for injection / infusion - filgrastim 0.6 mg/ml - filgrastim - filgrastim - tevagrastim is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. the safety and efficacy of tevagrastim are similar in adults and children receiving cytotoxic chemotherapy. tevagrastim is indicated for the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc). in patients children or adults with severe congenital neutropenia cyclic or idiopathic neutropenia with an absolute nuetrophil count (anc) less than or equal to 0.5 x 1000000000 /l and a history of severe or recurrent infections long term administration of tevagrastim is indicated to increase neutophil count and to reduce the incidence and duration of infection-related events. tevagrastim in indicated for the treatment of persistent neutopenia (anc less than or equal to 1.0 x 1000000000/l ) in patients with advanced hiv infection in order to reduce the risk of bacterial infections when other options to manage neutopenia are inappropriate.

Malta - Ingliż - Medicines Authority

amgen europe b.v. minervum 7061, 4817 zk breda, netherlands - filgrastim - solution for injection - filgrastim 0.3 mg/ml - immunostimulants

Malta - Ingliż - Medicines Authority

amgen europe b.v. minervum 7061, 4817 zk breda, netherlands - filgrastim - solution for injection - filgrastim 0.6 mg/ml - immunostimulants